Opdivo (nivolumab) Plus Yervoy (ipilimumab) Treatments: CheckMate 743 Study [Opdivo plus Yervoy treatments have] demonstrated long-term, durable survival benefit as first-line treatment in patients with various solid tumor types. The randomized phase III CheckMate 743 study demonstrated significant overall survival (OS) benefit with [Opdivo plus … [Read more...]
Nivolumab plus ipilimumab confers sustained OS benefit in malignant pleural mesothelioma
Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer. The open-label, multicenter CheckMate-743 trial included 605 patients who received six cycles of pemetrexed and … [Read more...]
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
Background: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab [(Opdivo)], an anti-PD-1 antibody, in these patients. Methods: This was a multicentre, … [Read more...]